Innoviva Inc Cash Flow Conversion Efficiency
Innoviva Inc cash flow conversion efficiency. Based on the latest financial reports, Innoviva Inc (INVA) has a cash flow conversion efficiency ratio of 0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($51.97 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Innoviva Inc (2002–2025)
Cash flow conversion efficiency of Innoviva Inc from 2002 to 2025. This chart illustrates how Innoviva Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INVA share price today for real-time trading data and today's change.
Innoviva Inc Cash Flow Conversion Ratio Explained
Innoviva Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Innoviva Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innoviva Inc ranked by their cash flow conversion efficiency. Also see INVA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alexander & Baldwin Holdings Inc
NYSE:ALEX
|
0.013x |
|
Petrosea Tbk
JK:PTRO
|
-0.024x |
|
FADU Inc.
KQ:440110
|
-0.122x |
|
Suzhou Gold Mantis Construction Decoration Co Ltd
SHE:002081
|
0.029x |
|
Acadia Healthcare Company Inc
NASDAQ:ACHC
|
0.022x |
|
SL Corp
KO:005850
|
0.023x |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
-0.077x |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
0.098x |
Annual Cash Flow Conversion Efficiency for Innoviva Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Innoviva Inc from 2002 to 2025. Review Innoviva Inc (INVA) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.17 Billion | $196.93 Million | 0.168x | -38.50% |
| 2024-12-31 | $691.16 Million | $188.69 Million | 0.273x | +30.63% |
| 2023-12-31 | $674.96 Million | $141.06 Million | 0.209x | -41.38% |
| 2022-12-31 | $565.79 Million | $201.73 Million | 0.357x | -48.46% |
| 2021-12-31 | $525.93 Million | $363.81 Million | 0.692x | +34.29% |
| 2020-12-31 | $607.84 Million | $313.11 Million | 0.515x | -31.55% |
| 2019-12-31 | $342.12 Million | $257.46 Million | 0.753x | -46.45% |
| 2018-12-31 | $159.05 Million | $223.53 Million | 1.405x | +340.64% |
| 2017-12-31 | $-242.71 Million | $141.75 Million | -0.584x | -238.05% |
| 2016-12-31 | $-352.99 Million | $60.98 Million | -0.173x | -458.49% |
| 2015-12-31 | $-327.50 Million | $10.13 Million | -0.031x | -105.29% |
| 2014-12-31 | $-223.35 Million | $-130.72 Million | 0.585x | +235.08% |
| 2013-12-31 | $299.12 Million | $-129.60 Million | -0.433x | +47.50% |
| 2012-12-31 | $155.03 Million | $-127.95 Million | -0.825x | -181.33% |
| 2011-12-31 | $-87.05 Million | $-88.34 Million | 1.015x | -69.72% |
| 2010-12-31 | $-22.42 Million | $-75.14 Million | 3.352x | +990.94% |
| 2009-12-31 | $-188.99 Million | $-58.06 Million | 0.307x | -58.50% |
| 2008-12-31 | $-134.95 Million | $-99.91 Million | 0.740x | -53.00% |
| 2007-12-31 | $-66.26 Million | $-104.37 Million | 1.575x | +195.16% |
| 2006-12-31 | $63.31 Million | $-104.79 Million | -1.655x | -68.17% |
| 2005-12-31 | $59.58 Million | $-58.65 Million | -0.984x | -291.79% |
| 2004-12-31 | $190.37 Million | $-47.82 Million | -0.251x | -337.58% |
| 2003-12-31 | $-299.57 Million | $-31.68 Million | 0.106x | -58.15% |
| 2002-12-31 | $-231.93 Million | $-58.60 Million | 0.253x | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more